Author Archives: admin


Vitamin C can target and kill cancer stem cells, study shows – Medical News Today

Cancer is currently one of the top killers worldwide, and the number of cancer cases is only expected to rise. Although there are a number of therapies available, most of them are toxic and cause serious side effects. New research examines the impact of the natural vitamin C on cancer cell growth.

Cancer is the second leading cause of death and disease worldwide, accounting for almost 9 million deaths in 2015, according to the World Health Organization (WHO).

The global number of new cases of cancer are expected to grow by around 70 percent in the next 20 years.

In the United States, the National Cancer Institute (NCI) estimate that almost 40 percent of U.S. men and women will have developed cancer at one point during their lives.

There are various treatment options available for cancer, but they are not always effective; most of them are toxic, and they tend to have a variety of side effects.

In some more aggressive cases, the cancer does not respond to treatment, and it is believed that cancer stem-like cells are the reason why the cancer comes back and metastasizes.

New research, published in the journal Oncotarget, examines the effectiveness of three natural substances, three experimental drugs, and one clinical drug in stopping the growth of these cancer stem cells (CSCs.)

The study was conducted by researchers from the University of Salford in Manchester in the United Kingdom, and was led by Dr. Gloria Bonuccelli.

In total, the researchers measured the impact of seven substances: the clinical drug stiripentol, three experimental drugs (actinonin, FK866, and 2-DG), and three natural substances (caffeic acid phenyl ester (CAPE), silibinin, and ascorbic acid (vitamin C).)

The research focused on the bioenergetic processes of CSCs, which enable the cells to live and multiply. The study aimed to disrupt the CSCs' metabolism and ultimately prevent their growth.

Of all the substances tested, the team found that actinonin and FK866 were the most effective. However, the natural products were also found to prevent the formation of CSCs, and vitamin C was 10 times more effective than the experimental drug 2-DG.

Additionally, the study revealed that ascorbic acid works by inhibiting glycolysis - the process by which glucose is broken down within the cell's mitochondria and turned into energy for the cell's proliferation.

Dr. Michael P. Lisanti, professor of translational medicine at the University of Salford, comments on the findings:

"We have been looking at how to target cancer stem cells with a range of natural substances including silibinin (milk thistle) and CAPE, a honey-bee derivative, but by far the most exciting are the results with vitamin C. Vitamin C is cheap, natural, nontoxic and readily available so to have it as a potential weapon in the fight against cancer would be a significant step."

"This is further evidence that vitamin C and other nontoxic compounds may have a role to play in the fight against cancer," says the study's lead author.

"Our results indicate it is a promising agent for clinical trials, and as an add-on to more conventional therapies, to prevent tumor recurrence, further disease progression, and metastasis," Bonuccelli adds.

Vitamin C has been shown to be a potent, nontoxic, anticancer agent by Nobel Prize winner Linus Pauling. However, to the authors' knowledge, this is the first study providing evidence that ascorbic acid can specifically target and neutralize CSCs.

Learn how 300 oranges' worth of vitamin C can impair cancer cells.

Here is the original post:
Vitamin C can target and kill cancer stem cells, study shows - Medical News Today

Treating sickle cell disease with gene therapy – Jamaica Observer

After nearly two years of debate about its possible benefits and risks, the gene editing technique is now here to stay.

An article in the December 27, 2015 edition of the Sunday Observer told of the first recorded use of the inexpensive CASPR-Cas9 gene editing technology to cut and splice out bad genes and replace them with healthy genes.

INHERITED DISEASE

A gene is a unit of heredity that is passed down from parent to child, and which carries characteristics that become apparent in the child. Each cell of the human body has around 25,000 genes, and each of those genes carry information that determines the individual traits or features of the person. So there is a gene for eye colour, hair colour, skin colour, and so on.

However, when some genes are defective or they undergo changes or mutation, illnesses can occur. Illnesses may also occur when there are missing genes which should have played a particular role. Some of the problems with genes may also be inherited from a parent.

One such illness well known to us in Jamaica is sickle cell disease. This is a severe hereditary disease in which the haemoglobin protein that is present in red blood cells to carry oxygen around the body is mutated and abnormal. Red blood cells are customarily round and circular in shape to flow smoothly through our blood vessels, but when oxygen levels are low in the bloodstream, the abnormal haemoglobin that is present in people with sickle cell disease cause the red blood cells to bend into a sickle crescent shape, making it difficult for them to flow through the tiny blood vessels of the body, and consequently may cause severe joint pains and other complications.

GENE THERAPY

The concept behind gene therapy is to use the technology of genetic engineering to replace abnormal genes with healthy ones.

Whilst this concept has been around for 30 years, the process became much more accessible with the development of the inexpensive CASPR-Cas9 gene editing technology around two years ago.

In April 2015, scientists in China were able to use the technology to splice out bad genes that were present in human embryonic stem cells and replace them with healthy ones. The stem cells, however, were never implanted into women at the time for their development into humans.

In December 2015, a speaker at the annual symposium of the American Society of Hematology described possible work in which an infant with sickle cell disease would have his or her blood stem cells edited to repair the haemoglobin gene, thereby preventing the formation of blood cells that would have caused sickling. The specific work would involve harvesting the blood stem cells of the diseased infant, editing them outside the body with a normal DNA sequence, then returning them to the infant in a bone marrow transplant.

ETHICAL CONCERNS

As this technique involved editing the haemoglobin gene within the somatic stem cell rather than in the embryonic stem cell, this choice was deemed by many to be the more ethically acceptable approach. Many people are very concerned that the gene editing technique may be used to make long-lasting hereditable changes at the embryo stage or on germ cells (human sperm or eggs), and some find this unacceptable.

This notwithstanding, in February 2016, the United Kingdom Fertilisation and Embryology Authority, who are the UK regulators on fertility matters, granted permission for scientists in London to edit the genomes (the complete set of genetic instructions, which includes all genes) of human embryos for research purposes. The developmental biologists were allowed to use the gene editing technique in healthy embryos to alter genes that are active within the first few days after fertilisation of the egg.

The approved research would utilise healthy human embryos that had been left over from in vitro fertilisation procedures performed in fertility clinics. However, the caveat was that the researchers should stop the research after seven days of study, and the researched embryos destroyed. The study would illuminate how the modification of genes could assist in developing treatments for infertility.

MOST RECENT SUCCESS

A report in the most recent edition of the New England Journal of Medicine informed that a teenage boy with sickle cell disease appeared to have been cured using the gene therapy technique. The treatment had stopped the painful symptoms of the disease, and the teenager was doing well.

Success stories such as this are normally the first step in efforts to reproduce the benefits obtained in individual cases by conducting clinical trials of the treatment on large groups of affected people. Hopefully we will hear of such studies and their outcomes in the near future.

Until preliminary results are verified, however, scepticism will exist regarding whether the positive results obtained in one person will be translated to many more people. Time will tell.

Derrick Aarons MD, PhD is a consultant bioethicist/family physician, a specialist in ethical issues in medicine, the life sciences and research, and is the Ethicist at the Caribbean Public Health Agency CARPHA. (The views expressed here are not written on behalf of CARPHA)

Original post:
Treating sickle cell disease with gene therapy - Jamaica Observer

For The First Time Ever, Scientists Have Successfully Created An … – Wall Street Pit

For The First Time Ever, Scientists Have Successfully Created An Artificial Embryo

It may soon become possible to grow artificial human life in a lab by using stem cells to create an actual embryo. While that might creep some people out because it sure sounds a lot like a precursor to designer babies or even clones, the scientists doing the research would like to make it clear that their intention is something totally different.

By growing embryos and replicating what happens during the early stages of reproduction, they are hoping that they will be able to understand why more than two out of three miscarriages happen, and use then this knowledge to prevent or at least minimize such unfortunate circumstances. In other words, the research is being done to help prevent the loss of lives, not create artificial ones.

Right now, scientists are only allowed to conduct experiments on embryos developed from egg cells donated through in vitro fertilization (IVF) clinics. There arent many of those, however. Plus, regulations (and ethics) dictate that they have to be destroyed after 14 days. But by being able to create their own unlimited supply of artificial embryos, research can be done faster and more extensively. As an added bonus, ethics will not be an issue.

To create the embryos, a research team from the University of Cambridge led by Professor Magdalena Zernicka-Goetz combined embryonic stem cells (ESCs) with extra-embryonic trophoblast stem cells or TSCs (the ones responsible for forming the placenta during a normal pregnancy).

Previous attempts to grow embryos didnt work because only embryonic stem cells were used and this prevented the cells from assembling in their correct positions. Adding the second type of placental stem cell solved this problem.

According to Professor Goetz, although they are aware that interaction between different types of stem cells is important for development, their experiment showed just how important that partnership was. After adding the extra-embryonic trophoblast stem cells, the two types of stem cells began communicating with each other, almost like guiding and telling each other where to go, what to do, and when to do it, until they were eventually able to form an embryo-like structure appearance-wise and behavior-wise, with separate clusters that will give rise to the different body organs, if development was allowed to continue.

The research team is quick to point out, however, that this is as far as they will allow it to progress. In other words, the artificial embryo will not continue to grow into a fetus because it will need a third type of stem cell for that one which forms the yolk sac that is responsible for providing nutrition.

So far, the technique has only been tested on mouse stem cells. Eventually, the team hopes to achieve the same results on human stem cells. And that might prove to be the key that can potentially help solve the problem of failed pregnancies in the future.

As Professor Goetz said in a statement she issued, the team is very optimistic that this will allow [them] to study key events of this critical stage of human development without actually having to work on embryos. Knowing how development normally occurs will allow us [noted Goetz] to understand why it so often goes wrong.

The research was recently published in the journal Science.

Continued here:
For The First Time Ever, Scientists Have Successfully Created An ... - Wall Street Pit

‘Butterfly Boy’ steels himself for second stem-cell transplant – Ottawa Citizen

Jonathan Pitre with his Boston terrier, Gibson. Tina Boileau / -

Bracing for his second stem-cell transplant in seven months, Jonathan Pitre knows all too well the mountain in front of him, its hardships and precipices.

So hes doing what he always does when confronted with such a steep challenge. Its all about staying positive, I think, Pitre, 16, said in a telephone interview from Minneapolis.

Theres no checklist to prepare for his perilous journey, and no book that can calm all his misgivings.

Its mostly thinking about sticking together with the people you care about, your family, he said of his preparation. You have to stick to them very, very tightly and tell each other that, Its going to be OK and that were stronger than this. Were going through this together, not just alone.

Pitre will face the transplant alongside his mother, Tina Boileau, who will also be his stem-cell donor.

Boileau has taken a second leave of absence from her government job to be at her sons side for a treatment that could keep them in Minnesota for six months or more.

Later this month, Pitre will undergo a series of tests to ensure his heart, kidneys and other organs are healthy enough to withstand the rigours of the transplant. Hes still fighting the effects of a cold, but the blood infection that put him in hospital last month has been brought under control.

According to his current treatment schedule, Pitre will be admitted to the University of Minnesota Masonic Childrens Hospital on March 28. Then, in early April, hell begineight days of high-dose chemo followed by one day of full-body radiation before his stem-cell transplant.

The chemo and radiation are designed to destroy his immune system and prevent it from attacking the donor cells.

Pitre is the first Canadian to take part in the clinical trial operated by the University of Minnesotas Dr. Jakub Tolar, a pediatric transplant specialist who has adapted stem-cell therapy as a treatment for the most severe forms of epidermolysis bullosa (EB). Its the only facility in the world that offers the treatment for EB patients.

Pitre suffers from recessive dystrophic EB, a rare, painful and deadly form of the disease.

Last September, Pitre suffered nausea, raging fevers and exhaustion in the aftermath of his first transplant, which ultimately failed when his own stem cells recolonized his bone marrow.

Pitre said he knows what to expect this time, but that doesnt necessarily make it easier. I know a lot of it was unpleasant. I know its going to happen again, he said. So I know a lot of that unpleasantness is going to come.

The Russell teenager, however, said hes prepared to face that future considering the promise that the transplants holds for him.

I think of my family, I think of Gibson (his Boston terrier) and I think of all the good things that will come from this procedure, and after the procedure, how much more Im going to be able to enjoy life, how much more Im going to be able to enjoy time with my family, with Gibson.

Although the procedure comes with life-threatening complications, it has produced dramatic improvements in two-thirds of those EB patients who have survived the transplant: tougher skin, reduced blistering and better wound healing.

Link:
'Butterfly Boy' steels himself for second stem-cell transplant - Ottawa Citizen

Stem cell therapy for the treatment of Peyronie’s disease. – UroToday – UroToday

Like other fibrotic diseases, the cause of Peyronie's disease (PD) is still obscure. Since there is now increasing evidence for the role of Mesenchymal Stem Cells (MSCs) as potential treatment to fibrosis, it is crucial to determine their possible efficacy in the treatment of PD. Areas covered: In this review, the authors summarize the emerging data and published studies regarding the use of SCs for the treatment of PD. The authors provide particular focus on the three-first experimental studies for the use of SCs in rat models as well as the sole two studies undertaken in humans. Expert opinion: It seems evident in experimental settings that SCs in general (Adipose Derived SCs in particular) provide a feasible, safe and effective therapy for PD. The potential limits of the rat models used initially have been somewhat overcome with the inception of studies in men. However, further prospective studies are needed in humans to further elucidate the therapeutic potential of stem cell therapy in PD.

Expert opinion on biological therapy. 2017 Feb 28 [Epub]

Athanasios Dellis, Athanasios Papatsoris

a University Department of Urology , Sismanoglio General Hospital , Athens , Greece.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/28274142

More here:
Stem cell therapy for the treatment of Peyronie's disease. - UroToday - UroToday

Stem cell reprogramming factor controls change in cellular energy generation – Science Daily

Stem cell reprogramming factor controls change in cellular energy generation
Science Daily
Now, research led by the University of Tsukuba has solved the mystery surrounding one of the reprogramming factors, KLF4. The study was published in Stem Cell Reports. KLF4 together with other reprogramming transcription factors is used in the lab to ...

Go here to see the original:
Stem cell reprogramming factor controls change in cellular energy generation - Science Daily

These comprise a small group of passive stem cells -quiescent- that are activated when needed and have the capacity … – Science Daily


Science Daily
These comprise a small group of passive stem cells -quiescent- that are activated when needed and have the capacity ...
Science Daily
Researchers at the Institute for Research in Biomedicine (IRB Barcelona) headed by ICREA investigator Eduard Batlle, head of the Colorectal Cancer Laboratory, have discovered a new group of intestinal stem cells with very different characteristics to ...
Nature Cell Started Commercial Clinical Trials Phase I and II 'ASTROSTEM,' Stem Cell Drug for Alzheimer's Disease ...Business Wire (press release)
Targeting cancer stem cells improves treatment effectiveness and prevents metastasisMedical Xpress
LifeCell launches community stem cell bankHindu Business Line

all 15 news articles »

View original post here:
These comprise a small group of passive stem cells -quiescent- that are activated when needed and have the capacity ... - Science Daily

Teen’s Sickle Cell Disease ‘Reversed’ with Groundbreaking Therapy – Reader’s Digest

chairoij/ShutterStockImagine having your spleen removed, undergoing a double hip replacement, and receiving monthly blood transfusions to prevent severe pain attacks, all by the age of 13. That was the life of a teenager in France with sickle cell disease (SCD) until October 2014, when he received experimental gene therapy as part of a clinical study. Now, hes completely off all medications and his SCD is essentially gone, making him the hopeful poster child for the worlds first effective sickle cell disease therapy. (Dont these medical miracles that doctors cant explain.)

Standard treatments were not able to control his SCD symptoms [but] since receiving the stem cell transplant with LentiGlobin, he has been free from severe symptoms and has resumed normal activities, without the need for further transfusions, said study author Marina Cavazzana, MD, PhD, of Necker Hospital in Paris, France, where the trial was conducted, in a news release.

SCD is a inherited blood disorder where sufferers have sickle hemoglobin, an abnormal form of the oxygen-carrying protein which changes the shape of red blood cells (from a flexible disc shape to a rigid crescent one), making it hard for them to pass through blood vessels and often causing blockages that slow or stop the flow of oxygen-rich blood to nearby tissues, causing sudden and severe pain. Sickled red blood cells also die after 10 to 20 days, compared to normal ones which can live up to 120; this can cause the body to have trouble keeping up with red blood cell production, leading to anemia. A stem-cell transplant is currently the only curative option for patients, but fewer than 18 percent of patients are able to find a matching donor.

That is until now. The 13-year-old boy (known as Patient 1204) had bone marrow extracted, which was then genetically altered with the drug LentiGlobin BB305 so that his body made normal, healthy red blood cells instead of the sickle cells it was creating before. After just six months, the proportions of sickled red cells in his blood were significantly lower than those in untreated SCD patients. Now more than 15 months since the treatment, his body is still producing normal red blood cells and he hasnt experience any SCD-related episodes or hospitalizations, according to the study published in the New England Journal of Medicine.

Ive worked in gene therapy for a long time and we make small steps and know theres years more work. But here you have someone who has received gene therapy and has complete clinical remissionthats a huge step forward, Deborah Gill, PhD, of the gene medicine research group at the University of Oxford in England told BBC.

Scientists plan to test the drug on other sickle cell disease patients to see if the results are replicated.

MORE: This Grandmother Beat Cancer in a Groundbreaking 20-Minute Treatment

See the article here:
Teen's Sickle Cell Disease 'Reversed' with Groundbreaking Therapy - Reader's Digest

Targeting cancer stem cells improves treatment effectiveness, prevents metastasis – Science Daily


Science Daily
Targeting cancer stem cells improves treatment effectiveness, prevents metastasis
Science Daily
Wang's research is published online in the peer-reviewed journal Cell Stem Cell. Cancer stem cells are known to be responsible for tumor formation and development; they also self-renew and tend to be unresponsive to cancer therapy. These cells have ...
Nature Cell Started Commercial Clinical Trials Phase I and II 'ASTROSTEM,' Stem Cell Drug for Alzheimer's Disease ...Business Wire (press release)
The intestine has a reservoir of stem cells that are resistant to chemotherapyPhys.Org
Stem Cell Therapy Market to Witness Robust Expansion Throughout ...Medgadget (blog)
Hindu Business Line -Science Times
all 15 news articles »

See the article here:
Targeting cancer stem cells improves treatment effectiveness, prevents metastasis - Science Daily

COMMENTARY: Saving a 10-year-old’s life but at what cost? – Globalnews.ca

;

A researcher pulls a frozen vial of human embryonic stem cells at the University of Michigan Center for Human Embryonic Stem Cell Research Laboratory in Ann Arbor, Mich.

Im no Nostradamus. Neither was Nostradamus, come to think of it. But one doesnt need to be to see how ethically icky, in the professional vernacular, the future of medicine is going to be.

To paraphrase Captain Kirk, our medical tools are growing faster than our wisdom. The future isnt now, yet, but its closer than we realized. And almost certainly closer than were ready for.

Consider the case of the Al Sabbagh family. They recently arrived in Canada from Syria, with their children, including their son, Mohamad. Mohamad is 10 and suffers from idiopathic aplastic anemia, a rare condition. Mohamad has a severe case, and it would likely be fatal if untreated.

READ MORE:Could you save his life? Edmonton boy needs to find stem cell match

His illness has left his body incapable of producing blood cells necessary to remain healthy. According to a report in the CBC, he requires twice-weekly blood transfusions at the Hospital for Sick Children in Toronto. Even with those, his quality of life has absolutely been impacted.

Theres a chance for Mohamad to live a healthy, normal life. A bone marrow transplant could restore his ability to produce the blood cells he needs. But the donor must be a very, very close match. Mohamads parents are not optimal donors, neither are his siblings. Its also possible to seek a donor through public donor banks, but you want as close a genetic match as possible.

Canadas Arab population is relatively small, and the number of those Canadian-Arabs whove put their information into a donor registry is even smaller. The odds for young Mohamad are long.

READ MORE:Quebec family hopes to raise awareness for patients in need with stem cell registry drive

Thats led his parents to consider a remarkable step. New embryos could be created, using in vitro fertilization techniques, using the genetic material of his parents. The embryos can then be genetically screened, with only the best match implanted into Mohamads mother for gestation and delivery. That baby could then be used to provide a potentially life-saving transplant of stem cells into Mohamad.

If all went well, Mohamads bone marrow would regenerate, curing his illness. The infant would not be endangered (the donor cells would be collected from the umbilical cord blood, not the infants body).

There aretwo equally valid ways of looking at this. Indeed, they should go hand-in-hand. As a father of two young children myself, I cant fault the Al Sabbaghs for wanting to save their son, at any cost. If my children were suffering and this was the best chance to cure them, I wouldnt hesitate to sign on whatever dotted lines were required. Adding a third child to our family would be a blessing. I confess to not consulting with my wife before writing that, so dont blow my cover, but if thats what it took, I know wed be on board.

READ MORE:Calgary boy meets stem cell donor who saved his life: its a miracle

But on the other hand, how can it not send chills down your spine to think of creating a human being purely to benefit someone else?

This is not a criticism of the Al Sabbaghs, nor of any other family that has previously conceived a so-called saviour sibling. I 100 per cent understand the urge to save the child you have. Theres no moral blame here. But good Lord, what a strange path were embarking on.

A few decades ago, this wouldnt have been possible. The Al Sabbagh family would have had limited choices.

Bone marrow transplants have been around since the 1970s, but the ability to conceive multiple children, genetically screen them for compatibility and then bring specifically the best match to term, is much newer. Its a small peek into a future were just arriving at.

READ MORE:I need a man: Ethnic donors desperately needed for bone marrow registry

Medical technology is advancing rapidly, and stem cells are a particularly promising field. But as we push these technological envelopes, were going to encounter tough moral dilemmas that we are not ready for. Indeed, we probably havent even thought of them yet.

Im not a medical ethicist, nor an expert in the field of stem cells and transplantation. But one doesnt need to be to wonder about the morality of creating a person to save another. Even if the saviour sibling lives a long, healthy and happy life, cherished by its parents and the brother it saved, you cant help but wonder what psychological toll it would take knowing you were, at birth, essentially raw materials. And its also not too hard to envision a future where this treatment could be used more broadly, with new life being created simply to cure the injuries and illnesses of those already living.

After all, why not? Dont the needs of the sick and dying today take precedence over people who only exist in theory?

It seems wild now, like something out of science fiction. But our sci-fi daydreams have a habit of becoming reality. Are we ready for what this would mean? Are we prepared for a future where children can be conceived and harvested for parts? Would we feel better if the raw material babies were genetically tweaked in such a way that they never developed consciousness, and were therefore something less than human? Would it soothe our consciences to breed human tissue to serve just as spare parts if the bodies never grew a brain?

None of this matters much for Mohamad, a 10-year-old boy lucky enough to be born in a time and now live in a place where modern medical miracles make curing his brutal illness possible. And no one should judge the desperation of a mom and dad who just want their son to live a long, healthy, normal life.

But consider this a case study, a sample of the future. We are moving into new frontiers in leaps and bounds. I hope to hell were ready for the questions well face once were there.

Matt Gurney is host of The Morning Show on Torontos Talk Radio AM640 and a columnist for Global News.

2017Global News, a division of Corus Entertainment Inc.

Originally posted here:
COMMENTARY: Saving a 10-year-old's life but at what cost? - Globalnews.ca